Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis

  Free Subscription


Articles published in AIDS

Retrieve available abstracts of 95 articles:
HTML format



Single Articles


    August 2021
  1. MICAN R, Busca Arenzana C, Vasquez J, Daroca G, et al
    Hepatitis B reactivation after tenofovir withdrawal in an HIV-infected patient with history of cured hepatitis B virus infection and poor immunological status.
    AIDS. 2021;35:1707-1708.
    PubMed    


  2. WINSLOW DL
    Hepatitis C virus infection and cardiac dysfunction in women.
    AIDS. 2021;35:1689-1690.
    PubMed    


    July 2021
  3. PECHEUR EI
    Circulating micro-RNAs as biomarkers of liver fibrosis progression in hepatitis C virus/HIV-1-co-infected patients: a 'miR'-velous opportunity of early diagnosis?
    AIDS. 2021;35:1499-1500.
    PubMed    


  4. RAMOS-RINCON JM, Pinargote H, Ramos-Belinchon C, de Mendoza C, et al
    Hepatitis delta in patients hospitalized in Spain (1997-2018).
    AIDS. 2021 Jul 13. pii: 00002030-900000000-96346.
    PubMed     Abstract available


    June 2021
  5. GUARDIGNI V, Toschi A, Badia L, Del Turco ER, et al
    Patients living with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for HCV.
    AIDS. 2021 Jun 4. pii: 00002030-900000000-96387.
    PubMed     Abstract available


    May 2021
  6. CORMA-GOMEZ A, Macias J, Tellez F, Morano L, et al
    Kinetics of emergence of liver complications in HCV-infected patients and advanced fibrosis, with and without HIV-coinfection, after SVR.
    AIDS. 2021 May 27. pii: 00002030-900000000-96392.
    PubMed     Abstract available


  7. HAMADY A, Cooke GS, Garvey LJ
    Identification of hepatitis delta superinfection when investigating transaminitis in HIV/HBV coinfection.
    AIDS. 2021 May 10. pii: 00002030-900000000-96410.
    PubMed     Abstract available


    April 2021
  8. HUNG R, Patel N, Fox J, Cosgrove C, et al
    Prevalence of HIV/hepatitis B and HIV/hepatitis C coinfection among people of East, South, Central and West African ancestry in the United Kingdom.
    AIDS. 2021 Apr 28. pii: 00002030-900000000-96416.
    PubMed     Abstract available


  9. SHITOLE SG, Lazar JM, Hanna DB, Kim RS, et al
    HIV, HCV and risk of new-onset left ventricular dysfunction: the women's interagency HIV study.
    AIDS. 2021 Apr 15. pii: 00002030-900000000-96421.
    PubMed     Abstract available


  10. PREININGER L, Kahal DA, Szabo S
    Hepatitis B vaccination response and safety in people living with HIV/AIDS receiving HepB-CpG series.
    AIDS. 2021;35:845-846.
    PubMed    


    March 2021
  11. FRANCO S, Buccione D, Tural C, Martinez MA, et al
    Circulating microRNA signatures that predict liver fibrosis progression in patients with HIV-1/HCV co-infections.
    AIDS. 2021 Mar 31. pii: 00002030-900000000-96441.
    PubMed     Abstract available


  12. FRENCH AL, Grennan D, Daubert E, Seaberg EC, et al
    Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/HCV co-infected women.
    AIDS. 2021 Mar 11. pii: 00002030-900000000-96468.
    PubMed     Abstract available


    February 2021
  13. FALADE-NWULIA O, Seaberg EC, Snider AE, Rinaldo CR, et al
    Outcomes of acute hepatitis B virus (HBV) in HIV infection with and without HBV-active antiretroviral therapy.
    AIDS. 2021 Feb 9. pii: 00002030-900000000-96487.
    PubMed     Abstract available


    November 2020

  14. Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases Consensus panel: Erratum.
    AIDS. 2020;34:2161-2163.
    PubMed    


    October 2020
  15. DES JARLAIS DC, Duong Thi H, Khuat Thi Hai O, Feelemyer JP, et al
    Ending an HIV epidemic among persons who inject drugs (PWID) in a middle-income country: extremely low HIV incidence among PWID in Hai Phong, Viet Nam.
    AIDS. 2020 Oct 8. doi: 10.1097/QAD.0000000000002712.
    PubMed     Abstract available


  16. SANTOS ME, Protopopescu C, Ribero RA, Benzaken AS, et al
    Population attributable fractions of mortality in people living with HIV: roles of delayed antiretroviral therapy, hepatitis coinfections and social factors.
    AIDS. 2020;34:1843-1854.
    PubMed     Abstract available


    September 2020
  17. CACHAY ER, Torriani FJ, Hill L, Jain S, et al
    The role of barriers to care on the propensity for hepatitis C virus nonreferral among people living with HIV.
    AIDS. 2020;34:1681-1683.
    PubMed     Abstract available


  18. MOLINA-ITURRITZA E, San-Jose-Muniz I, Ganchegui-Aguirre M, Balerdi-Sarasola L, et al
    Coronavirus disease 2019 in patients with HIV in the province of Araba, Basque Country, Spain.
    AIDS. 2020;34:1696-1697.
    PubMed    


    August 2020
  19. DEZANET LNC, Maylin S, Gabassi A, Rougier H, et al
    Correlation of serum hepatitis B core-related antigen with HBV total intrahepatic DNA and ccc-DNA viral load in HIV-hepatitis B coinfection.
    AIDS. 2020 Aug 7. doi: 10.1097/QAD.0000000000002659.
    PubMed     Abstract available


  20. MERCHANTE N, Rodriguez-Fernandez M, Figueruela B, Rodriguez-Arrondo F, et al
    Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients.
    AIDS. 2020;34:1497-1507.
    PubMed     Abstract available


  21. MOCROFT A, Ryom L, Oprea C, Li Q, et al
    Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons.
    AIDS. 2020;34:1485-1495.
    PubMed     Abstract available


  22. GIRON LB, Azzoni L, Yin X, Lynn KM, et al
    Hepatitis C virus modulates IgG glycosylation in HIV co-infected antiretroviral therapy suppressed individuals.
    AIDS. 2020;34:1461-1466.
    PubMed     Abstract available


    July 2020
  23. SANTOS ME, Protopopescu C, Ribeiro RA, Benzaken AS, et al
    Population attributable fractions of mortality in people living with HIV: roles of delayed ART, hepatitis coinfections and social factors.
    AIDS. 2020 Jul 23. doi: 10.1097/QAD.0000000000002621.
    PubMed     Abstract available


  24. CACHAY ER, Torriani FJ, Hill L, Jain S, et al
    The role of barriers to care on the propensity for HCV non-referral among people living with HIV.
    AIDS. 2020 Jul 21. doi: 10.1097/QAD.0000000000002610.
    PubMed     Abstract available


  25. BOESECKE C
    Recently acquired and early chronic hepatitis C in men having sex with men (MSM): Recommendations from the NEAT-ID consensus panel.
    AIDS. 2020 Jul 17. doi: 10.1097/QAD.0000000000002622.
    PubMed     Abstract available


  26. HOSSEINI-HOOSHYAR S, Martinello M, Yee J, Read P, et al
    Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
    AIDS. 2020;34:1347-1358.
    PubMed     Abstract available


    May 2020
  27. COSTINIUK CT, Jenabian MA
    Reply to: Benefits of cannabis use for metabolic disorders and survival in people living with HIV with or without hepatitis C.
    AIDS. 2020;34:955-956.
    PubMed    


  28. SANTOS ME, Protopopescu C, Zucman D, Marcellin F, et al
    Benefits of cannabis use for metabolic disorders and survival in people living with HIV with or without hepatitis C co-infection.
    AIDS. 2020;34:953-954.
    PubMed    


    March 2020
  29. RIAL-CRESTELO D, Sepulveda MA, Gonzalez-Gasca FJ, Geijo-Martinez P, et al
    Does fibrosis really regress in HIV/hepatitis C virus co-infected patients after treatment with direct antiviral agents?
    AIDS. 2020;34:427-432.
    PubMed     Abstract available


    February 2020
  30. CACHAY E
    Do we need to address stigma and mistrust to facilitate hepatitis C elimination among people living with HIV?
    AIDS. 2020;34:325-331.
    PubMed    


    January 2020
  31. GRAS J, Mahjoub N, Charreau I, Cotte L, et al
    Early diagnosis and risk factors of acute hepatitis C in high-risk MSM on preexposure prophylaxis.
    AIDS. 2020;34:47-52.
    PubMed     Abstract available


    December 2019
  32. BESSON C, Noel N, Lancar R, Prevot S, et al
    HCV or HBV coinfection and lymphoma risk in people living with HIV.
    AIDS. 2019 Dec 10. doi: 10.1097/QAD.0000000000002461.
    PubMed     Abstract available


    November 2019
  33. RIAL-CRESTELO D, Sepulveda MA, Gonzalez-Gasca FJ, Geijo-Martinez P, et al
    Does fibrosis really regress in HIV/HCV co-infected patients after treatment with direct-antiviral agents?
    AIDS. 2019 Nov 14. doi: 10.1097/QAD.0000000000002433.
    PubMed     Abstract available


  34. MARTINEZ-REBOLLAR M, Pascual PP, de la Mora L, Londono MC, et al
    Contributing awareness of autoimmune hepatitis in HIV patients.
    AIDS. 2019;33:2103-2105.
    PubMed    


    September 2019
  35. GRAS J, Mahjoub N, Charreau I, Cotte L, et al
    Early diagnosis and risk factors of acute hepatitis c in high-risk men who have sex with men on pre-exposure prophylaxis.
    AIDS. 2019 Sep 2. doi: 10.1097/QAD.0000000000002364.
    PubMed     Abstract available


    August 2019
  36. CAPPELLETTI A, Peri AM, Bisi L, Sabbatini F, et al
    Recurrent posterior reversible encephalopathy syndrome in an HIV-HCV coinfected liver transplant recipient.
    AIDS. 2019;33:1679-1681.
    PubMed    


    July 2019
  37. CEDARBAUM E, Ma Y, Scherzer R, Price JC, et al
    Contributions of HIV, HCV, and traditional vascular risk factors to peripheral artery disease in women.
    AIDS. 2019 Jul 22. doi: 10.1097/QAD.0000000000002319.
    PubMed     Abstract available


  38. MBAE M, Owen L, Elisha KK, Ndhere A, et al
    Excess early mortality in HIV/hepatitis B virus co-infected patients initiating antiretroviral therapy in Kenya.
    AIDS. 2019;33:1404-1406.
    PubMed    


    May 2019
  39. KRONFLI N, Bhatnagar SR, Hull MW, Moodie EEM, et al
    Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up.
    AIDS. 2019;33:1013-1022.
    PubMed     Abstract available


    March 2019
  40. BERENGUER J, Gil-Martin A, Jarrin I, Montes ML, et al
    Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals.
    AIDS. 2019;33:685-689.
    PubMed     Abstract available


  41. CORMA-GOMEZ A, Morano Amado L, Tellez F, Rivero-Juarez A, et al
    HIV infection does not impact on the risk of liver complications in HCV-infected patient with advanced fibrosis, after sustained virological response with DAA.
    AIDS. 2019 Mar 5. doi: 10.1097/QAD.0000000000002186.
    PubMed     Abstract available


  42. CHRISTIAN B, Fabian E, Macha I, Mpangala S, et al
    Hepatitis B virus coinfection is associated with high early mortality in HIV-infected Tanzanians on antiretroviral therapy.
    AIDS. 2019;33:465-473.
    PubMed     Abstract available


  43. MACHIELS JD, Braam EE, van Bentum P, van Vugt M, et al
    Vaccination with Fendrix of prior nonresponding patients with HIV has a high success rate.
    AIDS. 2019;33:503-507.
    PubMed     Abstract available


    January 2019
  44. NEWSUM AM, Kooij KW, Boyd A, Smit C, et al
    Progression of liver fibrosis following acute hepatitis C virus infection in HIV-positive MSM.
    AIDS. 2019 Jan 14. doi: 10.1097/QAD.0000000000002138.
    PubMed     Abstract available


  45. KRONFLI N, Bhatnagar SR, Hull MW, Moodie EEM, et al
    Trends in cause-specific mortality in HIV-Hepatitis C co-infection following hepatitis C treatment scale-up.
    AIDS. 2019 Jan 12. doi: 10.1097/QAD.0000000000002156.
    PubMed     Abstract available


    December 2018
  46. BERENGUER J, Gil-Martin A, Jarrin I, Montes ML, et al
    Reinfection by HCV following effective all-oral DAA therapy in HIV/HCV-coinfected individuals.
    AIDS. 2018 Dec 21. doi: 10.1097/QAD.0000000000002103.
    PubMed     Abstract available


    November 2018
  47. LOAREC A, Carnimeo V, Molfino L, Kizito W, et al
    Extremely Low Hepatitis C prevalence among HIV co-infected individuals in 4 countries in sub-Saharan Africa.
    AIDS. 2018 Nov 16. doi: 10.1097/QAD.0000000000002070.
    PubMed     Abstract available


    October 2018
  48. MOLINA-LEYVA A, Badiola J
    Severe refractory hidradenitis suppurativa successfully treated with adalimumab in an HIV-positive/hepatitis C virus-positive patient.
    AIDS. 2018;32:2436-2438.
    PubMed    


  49. ALDERSLEY J, Lorenz DR, Misra V, Uno H, et al
    Increased risk of anal squamous cell carcinoma in HIV-positive men with prior HBV infection.
    AIDS. 2018 Oct 16. doi: 10.1097/QAD.0000000000002059.
    PubMed     Abstract available


  50. VAN SANTEN DK, van der Helm JJ, Touloumi G, Pantazis N, et al
    Effect of incident hepatitis C infection on CD4 count and HIV RNA trajectories based on a multinational HIV seroconversion cohort.
    AIDS. 2018 Oct 15. doi: 10.1097/QAD.0000000000002040.
    PubMed     Abstract available


    August 2018
  51. LLEDO GM, Carrasco I, Benitez-Gutierrez LM, Arias A, et al
    Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection.
    AIDS. 2018 Aug 8. doi: 10.1097/QAD.0000000000001966.
    PubMed     Abstract available


  52. PRICE JC, Seaberg EC, Stosor V, Witt MD, et al
    AST-to-platelet ratio index increases significantly 3 years prior to liver-related death in HIV-hepatitis-coinfected men.
    AIDS. 2018 Aug 8. doi: 10.1097/QAD.0000000000001977.
    PubMed     Abstract available


    July 2018
  53. ROSSOTTI R, Maggioni M, Merli M, Orcese C, et al
    Severe cholestatic hepatitis related to abacavir/lamivudine/dolutegravir antiretroviral treatment in a HIV-1 infected subject.
    AIDS. 2018;32:1727-1729.
    PubMed    


  54. LACOMBE K
    Risk of hepatocellular carcinoma after DAA treatment in cirrhotic HIV-HCV-coinfected patients: where do we stand?
    AIDS. 2018;32:1533-1534.
    PubMed    


    June 2018
  55. LOUREIRO RV, Costa MN, Germano I, Calinas F, et al
    Pseudoresistance of hepatitis B virus to tenofovir with emtricitabine.
    AIDS. 2018;32:1387-1388.
    PubMed    


  56. PETERS L, Laut K, Resnati C, Del Campo S, et al
    Uptake of HCV treatment in HIV/HCV coinfected patients across europe in the era of direct-acting antivirals.
    AIDS. 2018 Jun 14. doi: 10.1097/QAD.0000000000001928.
    PubMed     Abstract available


  57. TARAMASSO L, Montanari L, Di Biagio A
    Hepatitis C virus direct acting antivirals impact on renal function in the first 4 weeks of treatment.
    AIDS. 2018;32:1202-1203.
    PubMed    


    April 2018
  58. ALMEIDA-BRASIL CC, Moodie EEM, Mclinden T, Hamelin AM, et al
    Medication non-adherence, multi-tablet regimens, and food insecurity are key experiences in the pathway to incomplete HIV suppression.
    AIDS. 2018 Apr 19. doi: 10.1097/QAD.0000000000001822.
    PubMed     Abstract available


    March 2018
  59. MERCHANTE N, Rodriguez-Arrondo F, Revollo B, Merino E, et al
    Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/HCV-coinfected patients.
    AIDS. 2018 Mar 28. doi: 10.1097/QAD.0000000000001809.
    PubMed     Abstract available


  60. LARMARANGE J, Becquet V, Masumbuko JM, Nouaman M, et al
    Implementing preexposure prophylaxis among key populations: an opportunity for patient-centered services and management of hepatitis B.
    AIDS. 2018;32:829-830.
    PubMed    


  61. VALENCIA J, Ryan P, Alvaro-Meca A, Troya J, et al
    High HIV seroconversion rate in HCV-infected drug users followed in a Harm Reduction Unit: A lost opportunity for Pre- exposure Prophylaxis.
    AIDS. 2018 Mar 20. doi: 10.1097/QAD.0000000000001806.
    PubMed     Abstract available


  62. ISMAIL MF, Wong DK, Bogoch II
    The role for hepatitis A vaccination in HIV pre-exposure prophylaxis.
    AIDS. 2018;32:675-676.
    PubMed    


    February 2018
  63. FARFOUR E, Lesprit P, Wai ACH, Mazaux L, et al
    Acute hepatitis A breakthrough in MSM in Paris area: implementation of targeted hepatitis A virus vaccine in a context of vaccine shortage.
    AIDS. 2018;32:531-532.
    PubMed    


  64. MEDRANO LM, Garcia-Broncano P, Berenguer J, Gonzalez-Garcia J, et al
    Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/HCV-coinfected patients.
    AIDS. 2018 Feb 12. doi: 10.1097/QAD.0000000000001787.
    PubMed     Abstract available


  65. PRADAT P, Huleux T, Raffi F, Delobel P, et al
    Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV.
    AIDS. 2018 Feb 12. doi: 10.1097/QAD.0000000000001789.
    PubMed     Abstract available


    January 2018
  66. MINGUEZ C, Garcia-Deltoro M, Flores J, Galindo MJ, et al
    Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients.
    AIDS. 2018;32:337-346.
    PubMed     Abstract available


  67. ROSSI C, Saeed S, Cox J, Vachon ML, et al
    Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients.
    AIDS. 2018 Jan 23. doi: 10.1097/QAD.0000000000001750.
    PubMed     Abstract available


  68. WILLIS SJ, Cole SR, Westreich D, Edmonds A, et al
    Chronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapy.
    AIDS. 2018 Jan 13. doi: 10.1097/QAD.0000000000001745.
    PubMed     Abstract available


  69. YOSHIMURA Y, Miyata N, Komatsu H, Tachikawa N, et al
    Remarkable plasma HIV RNA decrease by ombitasvir/paritaprevir/ritonavir in an HIV-HCV coinfection case.
    AIDS. 2018;32:128-129.
    PubMed    


    December 2017
  70. NGUYEN VK, Greenwald ZR, Trottier H, Cadieux M, et al
    Incidence of sexually transmitted infections before and after Pre-Exposure Prophylaxis for HIV: a cohort study.
    AIDS. 2017 Dec 12. doi: 10.1097/QAD.0000000000001718.
    PubMed     Abstract available


    November 2017
  71. LI F, Ma L, Feng Y, Ruan Y, et al
    HIV-1 and Hepatitis C virus selection bottleneck in Chinese people who inject drugs.
    AIDS. 2017 Nov 30. doi: 10.1097/QAD.0000000000001702.
    PubMed     Abstract available


  72. KUNIHOLM MH, Liang H, Anastos K, Gustafson D, et al
    Association of a 3' untranslated region polymorphism in proprotein convertase subtilisin/kexin type 9 with HIV viral load and CD4+ levels in HIV/hepatitis C virus coinfected women.
    AIDS. 2017;31:2483-2492.
    PubMed     Abstract available


  73. MINGUEZ C, Garcia-Deltoro M, Flores J, Galindo MJ, et al
    Interferon-free therapy for treating HCV in difficult-to-treat HIV-coinfected patients as implemented in routine medical practice.
    AIDS. 2017 Nov 10. doi: 10.1097/QAD.0000000000001699.
    PubMed     Abstract available


    October 2017
  74. TARTAGLIA A, Ferrara SM, Sica S, Santantonio T, et al
    Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
    AIDS. 2017;31:2314-2315.
    PubMed    


    September 2017
  75. ZOBOLI F, Ripamonti D, Benatti SV, Comi L, et al
    Autoimmune hepatitis and HIV infection: two case reports and review of the literature.
    AIDS. 2017;31:2172-2175.
    PubMed    


  76. LAKE AC
    Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy.
    AIDS. 2017;31:2115-2118.
    PubMed     Abstract available


  77. THORNTON AC, Jose S, Bhagani S, Chadwick D, et al
    Hepatitis B, hepatitis C and mortality among HIV-positive individuals.
    AIDS. 2017 Sep 18. doi: 10.1097/QAD.0000000000001646.
    PubMed     Abstract available


  78. KUNIHOLM MH, Liang H, Anastos K, Gustafson D, et al
    Association of a 3' Untranslated Region Polymorphism in PCSK9 with HIV Viral Load and CD4+ Levels in HIV/Hepatitis C Virus Co-Infected Women.
    AIDS. 2017 Sep 18. doi: 10.1097/QAD.0000000000001648.
    PubMed     Abstract available


    July 2017
  79. SARIS J, van den Berk G, Moha DA, van der Meer J, et al
    Successful implementation of hepatitis C virus treatment in two large HIV clinics in Amsterdam: hepatitis C virus treatment cascade of care.
    AIDS. 2017;31:1779-1780.
    PubMed    


  80. LEBRUN D, Hentzien M, Cuzin L, Rey D, et al
    Epidemiology of autoimmune and inflammatory diseases in a French Nationwide HIV cohort.
    AIDS. 2017 Jul 18. doi: 10.1097/QAD.0000000000001603.
    PubMed     Abstract available


  81. HOORNENBORG E, Achterbergh RCA, Schim van der Loeff MF, Davidovich U, et al
    MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection.
    AIDS. 2017;31:1603-1610.
    PubMed     Abstract available


  82. ZENG H, Wang L, Liu P, Liao L, et al
    Seroprevalence of hepatitis E virus in HIV-infected patients in China.
    AIDS. 2017 Jul 7. doi: 10.1097/QAD.0000000000001585.
    PubMed     Abstract available


  83. SINGH KP, Crane M, Audsley J, Lewin SR, et al
    HIV-hepatitis B virus co-infection: epidemiology, pathogenesis, and treatment.
    AIDS. 2017 Jul 7. doi: 10.1097/QAD.0000000000001574.
    PubMed     Abstract available


  84. VANHOMMERIG JW, Bezemer D, Molenkamp R, Van Sighem AI, et al
    Limited overlap between phylogenetic HIV and HCV clusters illustrates the dynamic sexual network structure of Dutch HIV-infected MSM.
    AIDS. 2017 Jul 7. doi: 10.1097/QAD.0000000000001592.
    PubMed     Abstract available


    June 2017
  85. TODESCO E, Demeret S, Calin R, Roque-Afonso AM, et al
    Chronic hepatitis E in HIV/HBV coinfected patient: lack of power of sofosbuvir-ribavirin.
    AIDS. 2017;31:1346-1348.
    PubMed    


  86. GRIESBECK M, Valantin MA, Lacombe K, Samri-Hassimi A, et al
    Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals.
    AIDS. 2017;31:1223-1234.
    PubMed     Abstract available


    May 2017
  87. MEIJIDE H, Pertega S, Rodriguez-Osorio I, Castro-Iglesias A, et al
    Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected.
    AIDS. 2017;31:1099-1107.
    PubMed     Abstract available


  88. HOORNENBORG E, Achterbergh RCA, Schim Van Der Loeff MF, Davidovich U, et al
    Men who have sex with men starting pre-exposure prophylaxis (PrEP) are at risk of HCV infection: evidence from the Amsterdam PrEP study.
    AIDS. 2017 May 1. doi: 10.1097/QAD.0000000000001522.
    PubMed     Abstract available


    March 2017
  89. MONTES ML, Olveira A, Ahumada A, Aldamiz T, et al
    Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection.
    AIDS. 2017 Mar 29. doi: 10.1097/QAD.0000000000001465.
    PubMed     Abstract available


  90. MEIJIDE H, Pertega S, Rodriguez-Osorio I, Castro-Iglesias A, et al
    Increased incidence of cancer observed in HIV/HCV-coinfected patients versus HIV-monoinfected, 1993-2014.
    AIDS. 2017 Mar 21. doi: 10.1097/QAD.0000000000001448.
    PubMed     Abstract available


  91. PRICE H, Dunn D, Zachary T, Vudriko T, et al
    Hepatitis B serological markers and plasma DNA concentrations: baseline results from the DART trial.
    AIDS. 2017 Mar 21. doi: 10.1097/QAD.0000000000001454.
    PubMed     Abstract available


  92. GRIESBECK M, Valantin MA, Lacombe K, Samri-Hassimi A, et al
    HCV drives increased type I IFN-associated impairments associated to fibrosis severity in ART-treated HIV-1-HCV coinfected individuals.
    AIDS. 2017 Mar 21. doi: 10.1097/QAD.0000000000001455.
    PubMed     Abstract available


    January 2017
  93. STREECK H, Verheyen J, Storim J, Dittmer U, et al
    Pre-exposure prophylaxis failure with tenofovir disoproxil.
    AIDS. 2017;31:176-177.
    PubMed    


    November 2016
  94. YOUNAS M, Carrat F, Finge S, Desaint C, et al
    Immune activation, smoking, and vaccine response.
    AIDS. 2016.
    PubMed     Abstract available


    March 2016
  95. AUDSLEY J, Bent SJ, Littlejohn M, Avihingsanon A, et al
    Effects of long-term tenofovir-based cART in HIV-HBV co-infection on persistent HBV viremia and the role of HBV quasispecies diversity.
    AIDS. 2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: